Bourne Partners, a healthcare-focused private equity investor and investment bank, is investing in a joint venture with The Emerson Group, an international consumer products equity organization, to build a global consumer health and wellness platform focused on acquiring and commercializing branded, over the counter (OTC) medications and personal care brands. This new venture, known as Daybreak Consumer Care (Daybreak), seeks to unite Bourne’s market expertise, product acquisition track record, and platform capabilities with The Emerson Group’s strategic relationships, substantial sector knowledge, and diverse value-added services for consumer companies. Daybreak will focus on acquiring other consumer healthcare companies and strategically-aligned brand portfolios. The combined track record and industry expertise of Bourne Partners and The Emerson Group provides a unique operating and investment platform.
 
“We value our relationship with Bourne Partners,” said Scott Emerson, president, The Emerson Group. “Bourne Partners has proven transactional experience across pharma and consumer health. Formalizing the relationship with Bourne is a reflection of our belief that the partnership can provide real solutions to consumers who need effective OTC treatments and desire high quality personal care products. We look forward to working with the Bourne team to build this company, deliver value to our retail partners and, most importantly, the end consumer.”
 
Banks Bourne, founder and chief executive officer, Bourne Partners, said, “We have known of The Emerson Group and its outstanding reputation for many years up and down the value chain. We have built a great relationship between two entrepreneurial organizations that will only continue to grow. With Bourne’s transaction and investing expertise, coupled with Emerson’s world-class strategic brand activation capabilities, we believe Daybreak will have the opportunity to scale and execute to achieve our ambitious goals. Throughout our firm’s history, we have partnered with nearly all of Big Pharma as acquirers and stewards of legacy brands. Our goal with this new joint venture is to deploy up to $500 million or more of equity into this platform over time. We are excited to bid on companies and assets across the globe in combination with our domestic, international, and global partners.”